Home > Newsletters > Drug Industry Daily > Independent Study Is Good News for Lilly’s Solanezumab in Early Alzheimer’s Treatment
Drug Industry Daily
Oct. 31, 2012 | Vol. 11 No. 214
Independent Study Is Good News for Lilly’s Solanezumab in Early Alzheimer’s Treatment
An independent analysis by the Alzheimer’s Disease Cooperative Study (ADCS) has found higher beta amyloid levels in the blood of patients treated with Eli Lilly’s Alzheimer’s candidate solanezumab compared with placebo.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.